<?xml version="1.0" encoding="UTF-8"?>
<p>The SHARED study (“Simplifying Hepatitis C Antiviral Treatment in Rwanda for Elsewhere in the Developing World”) was a single‐arm prospective study (n = 300) evaluating the antiviral efficacy, safety, and tolerability of LDV/SOF in adults with chronic HCV infection GT 1 or 4 in Rwanda.
 <xref rid="hep41482-bib-0011" ref-type="ref">11</xref> SHARED‐2 was a study embedded within SHARED that evaluated the safety and efficacy of a limited lab‐monitoring schedule in 60 consecutively enrolled participants (Fig. 
 <xref rid="hep41482-fig-0001" ref-type="fig">1</xref>). Here we report the results of SHARED‐2 and compare the results to the 240 SHARED‐1 participants who had guideline‐based on‐treatment lab monitoring during the study.
</p>
